INTRODUCTION: Fatigue and excessive daytime sleepiness are frequent complaints in myotonic dystrophy type 1 (DM1) that often overlap. We aimed to construct a combined fatigue and daytime sleepiness rating scale for DM1 using the Rasch measurement model. METHODS: Questionnaires, including the Epworth sleepiness scale, fatigue severity scale, and daytime sleepiness scale, were completed by 354 patients. Data were subjected to Rasch analyses and tested for required measurement issues such as appropriate response categories, absence of item bias, local independence, and unidimensionality. RESULTS: The initial 22 items did not meet Rasch model expectations. After rescoring and removing misfitting items, the final 12-item scale showed good model fit and unidimensionality. High internal consistency (person separation index = 0.80) and validity were demonstrated. CONCLUSIONS: The Rasch-built Fatigue and Daytime Sleepiness Scale, developed specifically for DM1 patients, provides interval measures on a single continuum. Its use is suggested for future clinical trials and therapeutic follow-up.
INTRODUCTION:Fatigue and excessive daytime sleepiness are frequent complaints in myotonic dystrophy type 1 (DM1) that often overlap. We aimed to construct a combined fatigue and daytime sleepiness rating scale for DM1 using the Rasch measurement model. METHODS: Questionnaires, including the Epworth sleepiness scale, fatigue severity scale, and daytime sleepiness scale, were completed by 354 patients. Data were subjected to Rasch analyses and tested for required measurement issues such as appropriate response categories, absence of item bias, local independence, and unidimensionality. RESULTS: The initial 22 items did not meet Rasch model expectations. After rescoring and removing misfitting items, the final 12-item scale showed good model fit and unidimensionality. High internal consistency (person separation index = 0.80) and validity were demonstrated. CONCLUSIONS: The Rasch-built Fatigue and Daytime Sleepiness Scale, developed specifically for DM1patients, provides interval measures on a single continuum. Its use is suggested for future clinical trials and therapeutic follow-up.
Authors: Bettine A H Vosse; Charlotte Seijger; Nicolle Cobben; Baziel van Engelen; Sander M J van Kuijk; Catharina Faber; Peter Wijkstra Journal: Respiration Date: 2021-05-07 Impact factor: 3.580
Authors: Libby Wood; Isabell Cordts; Antonio Atalaia; Chiara Marini-Bettolo; Paul Maddison; Margaret Phillips; Mark Roberts; Mark Rogers; Simon Hammans; Volker Straub; Richard Petty; Richard Orrell; Darren G Monckton; Nikoletta Nikolenko; Aura Cecilia Jimenez-Moreno; Rachel Thompson; David Hilton-Jones; Chris Turner; Hanns Lochmüller Journal: J Neurol Date: 2017-04-10 Impact factor: 4.849
Authors: Mark J Hamilton; John McLean; Sarah Cumming; Bob Ballantyne; Josephine McGhie; Ravi Jampana; Cheryl Longman; Jonathan J Evans; Darren G Monckton; Maria Elena Farrugia Journal: Front Neurol Date: 2018-10-02 Impact factor: 4.003